Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

Treatment of postmenopausal osteoporosis with transdermal estrogen.

Lufkin EG, Wahner HW, O'Fallon WM, Hodgson SF, Kotowicz MA, Lane AW, Judd HL, Caplan RH, Riggs BL.

Ann Intern Med. 1992 Jul 1;117(1):1-9.

PMID:
1534476
2.

Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial.

Greenspan SL, Emkey RD, Bone HG, Weiss SR, Bell NH, Downs RW, McKeever C, Miller SS, Davidson M, Bolognese MA, Mulloy AL, Heyden N, Wu M, Kaur A, Lombardi A.

Ann Intern Med. 2002 Dec 3;137(11):875-83.

PMID:
12458987
4.

Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study.

McCloskey E, Selby P, Davies M, Robinson J, Francis RM, Adams J, Kayan K, Beneton M, Jalava T, Pylkkänen L, Kenraali J, Aropuu S, Kanis JA.

J Bone Miner Res. 2004 May;19(5):728-36. Epub 2004 Jan 19.

6.

Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.

Ensrud KE, Black DM, Palermo L, Bauer DC, Barrett-Connor E, Quandt SA, Thompson DE, Karpf DB.

Arch Intern Med. 1997 Dec 8-22;157(22):2617-24.

PMID:
9531231
7.

Effect of microdose transdermal 17beta-estradiol compared with raloxifene in the prevention of bone loss in healthy postmenopausal women: a 2-year, randomized, double-blind trial.

Schaefers M, Muysers C, Alexandersen P, Christiansen C.

Menopause. 2009 May-Jun;16(3):559-65. doi: 10.1097/gme.0b013e31818ebfba.

PMID:
19423999
8.

Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial.

Reginster JY, Felsenberg D, Pavo I, Stepan J, Payer J, Resch H, Glüer CC, Mühlenbacher D, Quail D, Schmitt H, Nickelsen T.

Osteoporos Int. 2003 Sep;14(9):741-9. Epub 2003 Jun 19.

PMID:
12827224
9.

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M.

N Engl J Med. 1995 Nov 30;333(22):1437-43.

10.

Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study.

Palomba S, Manguso F, Orio F Jr, Russo T, Oppedisano R, Sacchinelli A, Falbo A, Tolino A, Zullo F, Mastrantonio P.

Menopause. 2008 Jul-Aug;15(4 Pt 1):730-6. doi: 10.1097/gme.0b013e318159f190.

PMID:
18698280
11.

Pulsed estrogen therapy in prevention of postmenopausal osteoporosis. A 2-year randomized, double blind, placebo-controlled study.

Nielsen TF, Ravn P, Bagger YZ, Warming L, Christiansen C.

Osteoporos Int. 2004 Feb;15(2):168-74. Epub 2003 Nov 25.

PMID:
14647880
12.

Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease.

Palomba S, Orio F Jr, Manguso F, Falbo A, Russo T, Tolino A, Tauchmanovà L, Colao A, Doldo P, Mastrantonio P, Zullo F.

Osteoporos Int. 2005 Sep;16(9):1141-9. Epub 2005 Jun 1.

PMID:
15928801
13.

Slow-release sodium fluoride in the management of postmenopausal osteoporosis. A randomized controlled trial.

Pak CY, Sakhaee K, Piziak V, Peterson RD, Breslau NA, Boyd P, Poindexter JR, Herzog J, Heard-Sakhaee A, Haynes S, Adams-Huet B, Reisch JS.

Ann Intern Med. 1994 Apr 15;120(8):625-32.

PMID:
8135445
14.

Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen.

Gallagher JC, Kable WT, Goldgar D.

Am J Med. 1991 Feb;90(2):171-8.

PMID:
1847582
15.

Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study.

Silverman SL, Chines AA, Kendler DL, Kung AW, Teglbjærg CS, Felsenberg D, Mairon N, Constantine GD, Adachi JD; Bazedoxifene Study Group..

Osteoporos Int. 2012 Jan;23(1):351-63. doi: 10.1007/s00198-011-1691-1. Epub 2011 Jul 21.

PMID:
21779819
17.

Osteoporosis prevention clinical study program.

Delmas P, Gimona A.

Eur J Obstet Gynecol Reprod Biol. 1996 Apr;64 Suppl:S39-45.

PMID:
8732473
18.

Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial.

Ravn P, Bidstrup M, Wasnich RD, Davis JW, McClung MR, Balske A, Coupland C, Sahota O, Kaur A, Daley M, Cizza G.

Ann Intern Med. 1999 Dec 21;131(12):935-42.

PMID:
10610644
19.

Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.

Jolly EE, Bjarnason NH, Neven P, Plouffe L Jr, Johnston CC Jr, Watts SD, Arnaud CD, Mason TM, Crans G, Akers R, Draper MW.

Menopause. 2003 Jul-Aug;10(4):337-44.

PMID:
12851517
20.

Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial.

Ettinger B, Ensrud KE, Wallace R, Johnson KC, Cummings SR, Yankov V, Vittinghoff E, Grady D.

Obstet Gynecol. 2004 Sep;104(3):443-51.

PMID:
15339752

Supplemental Content

Support Center